Literature DB >> 19129440

Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.

Wendy W Yeh1, Pimkwan Jaru-Ampornpan, Daiva Nevidomskyte, Mohammed Asmal, Srinivas S Rao, Adam P Buzby, David C Montefiori, Bette T Korber, Norman L Letvin.   

Abstract

Although there is increasing evidence that individuals already infected with human immunodeficiency virus type 1 (HIV-1) can be infected with a heterologous strain of the virus, the extent of protection against superinfection conferred by the first infection and the biologic consequences of superinfection are not well understood. We explored these questions in the simian immunodeficiency virus (SIV)/rhesus monkey model of HIV-1/AIDS. We infected cohorts of rhesus monkeys with either SIVmac251 or SIVsmE660 and then exposed animals to the reciprocal virus through intrarectal inoculations. Employing a quantitative real-time PCR assay, we determined the replication kinetics of the two strains of virus for 20 weeks. We found that primary infection with a replication-competent virus did not protect against acquisition of infection by a heterologous virus but did confer relative control of the superinfecting virus. In animals that became superinfected, there was a reduction in peak replication and rapid control of the second virus. The relative susceptibility to superinfection was not correlated with CD4(+) T-cell count, CD4(+) memory T-cell subsets, cytokine production by virus-specific CD8(+) or CD4(+) cells, or neutralizing antibodies at the time of exposure to the second virus. Although there were transient increases in viral loads of the primary virus and a modest decline in CD4(+) T-cell counts after superinfection, there was no evidence of disease acceleration. These findings indicate that an immunodeficiency virus infection confers partial protection against a second immunodeficiency virus infection, but this protection may be mediated by mechanisms other than classical adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129440      PMCID: PMC2648285          DOI: 10.1128/JVI.02237-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection.

Authors:  Maria Pernas; Concepción Casado; Rosa Fuentes; Maria Jesús Pérez-Elías; Cecilio López-Galíndez
Journal:  J Acquir Immune Defic Syndr       Date:  2006-05       Impact factor: 3.731

2.  Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

Authors:  Davey M Smith; Matthew C Strain; Simon D W Frost; Satish K Pillai; Joseph K Wong; Terri Wrin; Yang Liu; Christos J Petropolous; Eric S Daar; Susan J Little; Douglas D Richman
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

3.  Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8).

Authors:  Neil Berry; Richard Stebbings; Debbie Ferguson; Claire Ham; Jack Alden; Stuart Brown; Adrian Jenkins; Jenny Lines; Laura Duffy; Leanne Davis; William Elsley; Mark Page; Robin Hull; Jim Stott; Neil Almond
Journal:  J Gen Virol       Date:  2008-09       Impact factor: 3.891

4.  CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus.

Authors:  Richard Stebbings; Neil Berry; Herman Waldmann; Pru Bird; Geoff Hale; Jim Stott; David North; Robin Hull; Joanna Hall; Jenny Lines; Stuart Brown; Nikki D'Arcy; Leanne Davis; William Elsley; Cherry Edwards; Deborah Ferguson; Jane Allen; Neil Almond
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251.

Authors:  L Wakrim; R Le Grand; B Vaslin; A Chéret; F Matheux; F Theodoro; P Roques; I Nicol-Jourdain; D Dormont
Journal:  Virology       Date:  1996-07-15       Impact factor: 3.616

6.  Loss of naïve cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques.

Authors:  Yoshiaki Nishimura; Tatsuhiko Igarashi; Alicia Buckler-White; Charles Buckler; Hiromi Imamichi; Robert M Goeken; Wendy R Lee; Bernard A P Lafont; Russ Byrum; H Clifford Lane; Vanessa M Hirsch; Malcolm A Martin
Journal:  J Virol       Date:  2006-11-08       Impact factor: 5.103

7.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

Authors:  M S Wyand; K H Manson; M Garcia-Moll; D Montefiori; R C Desrosiers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.

Authors:  Catherine A Blish; Ozge C Dogan; Nina R Derby; Minh-An Nguyen; Bhavna Chohan; Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

9.  Examination of a second region of the HIV type 1 genome reveals additional cases of superinfection.

Authors:  Anne Piantadosi; Musa Otieno Ngayo; Bhavna Chohan; Julie Overbaugh
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

10.  Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.

Authors:  Matthew R Reynolds; Andrea M Weiler; Kim L Weisgrau; Shari M Piaskowski; Jessica R Furlott; Jason T Weinfurter; Masahiko Kaizu; Taeko Soma; Enrique J León; Caitlin MacNair; Dan P Leaman; Michael B Zwick; Emma Gostick; Solomon K Musani; David A Price; Thomas C Friedrich; Eva G Rakasz; Nancy A Wilson; Adrian B McDermott; Rosanne Boyle; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Exp Med       Date:  2008-10-06       Impact factor: 14.307

View more
  25 in total

Review 1.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

2.  Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Authors:  Lilin Lai; Suefen Kwa; Pamela A Kozlowski; David C Montefiori; Guido Ferrari; Welkin E Johnson; Vanessa Hirsch; Francois Villinger; Lakshmi Chennareddi; Patricia L Earl; Bernard Moss; Rama Rao Amara; Harriet L Robinson
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

3.  Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.

Authors:  Matthew R Reynolds; Andrea M Weiler; Shari M Piaskowski; Holly L Kolar; Ann J Hessell; Madelyn Weiker; Kim L Weisgrau; Enrique J León; W Eric Rogers; Robert Makowsky; Adrian B McDermott; Rosanne Boyle; Nancy A Wilson; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Ishita Rahman; Peter Hraber; Rory T Coffey; Daiva Nevidomskyte; Ayush Giri; Mohammed Asmal; Svetlana Miljkovic; Marcus Daniels; James B Whitney; Brandon F Keele; Beatrice H Hahn; Bette T Korber; George M Shaw; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

5.  Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages.

Authors:  Will Fischer; Cristian Apetrei; Mario L Santiago; Yingying Li; Rajeev Gautam; Ivona Pandrea; George M Shaw; Beatrice H Hahn; Norman L Letvin; Gary J Nabel; Bette T Korber
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

6.  Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.

Authors:  L Jean Patterson; Mara Daltabuit-Test; Peng Xiao; Jun Zhao; William Hu; Ulrike Wille-Reece; Egidio Brocca-Cofano; V S Kalyanaraman; Irene Kalisz; Stephen Whitney; Eun Mi Lee; Ranajit Pal; David C Montefiori; Satya Dandekar; Robert Seder; Mario Roederer; Roger W Wiseman; Vanessa Hirsch; Marjorie Robert-Guroff
Journal:  Virology       Date:  2011-01-14       Impact factor: 3.616

Review 7.  Is an HIV vaccine possible?

Authors:  Nancy A Wilson; David I Watkins
Journal:  Braz J Infect Dis       Date:  2009-08       Impact factor: 1.949

8.  The role of virulence in in vivo superinfection fitness of the vertebrate RNA virus infectious hematopoietic necrosis virus.

Authors:  Alison M Kell; Andrew R Wargo; Gael Kurath
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

9.  SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

Authors:  Robert Sealy; Xiaoyan Zhan; Timothy D Lockey; Louis Martin; James Blanchard; Vicki Traina-Dorge; Julia L Hurwitz
Journal:  Curr HIV Res       Date:  2009-09       Impact factor: 1.581

10.  Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Authors:  Nancy A Wilson; Brandon F Keele; Jason S Reed; Shari M Piaskowski; Caitlin E MacNair; Andrew J Bett; Xiaoping Liang; Fubao Wang; Elizabeth Thoryk; Gwendolyn J Heidecker; Michael P Citron; Lingyi Huang; Jing Lin; Salvatore Vitelli; Chanook D Ahn; Masahiko Kaizu; Nicholas J Maness; Matthew R Reynolds; Thomas C Friedrich; John T Loffredo; Eva G Rakasz; Stephen Erickson; David B Allison; Michael Piatak; Jeffrey D Lifson; John W Shiver; Danilo R Casimiro; George M Shaw; Beatrice H Hahn; David I Watkins
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.